Clomipramine

Clomipramine is a tricyclic antidepressant first developed in 1964 and still considered the most potent serotonin reuptake inhibitor available. People typically come to it for one of two reasons: severe obsessive-compulsive disorder that hasn't responded to SSRIs, or premature ejaculation, where even small doses can extend time to climax by several minutes.

It's not a first-line drug. Most psychiatrists reach for an SSRI first because clomipramine has a heavier side-effect load (dry mouth, sedation, weight gain, sexual dysfunction) and a real, dose-dependent seizure risk. But for the right person, especially someone with treatment-resistant OCD or lifelong PE, the trade-off can be worth it. Multiple meta-analyses still show it slightly outperforms SSRIs for OCD symptom reduction, even after correcting for trial bias.

Deep-dive

Clomipramine blocks the serotonin transporter with an affinity comparable to paroxetine, the most potent SSRI. That alone is unusual for a TCA, the rest of the class leans more toward norepinephrine. But clomipramine has a twist: it gets metabolised in the liver into desmethylclomipramine, which is a strong norepinephrine reuptake inhibitor. So the parent drug pushes serotonin up, the metabolite pushes norepinephrine up, and you get a dual-action effect not seen with SSRIs.

It also blocks histamine, acetylcholine, and alpha-adrenergic receptors, which is where most of the side effects come from. The antihistamine action drives sedation and weight gain. The anticholinergic action causes dry mouth, constipation, blurred vision, and urinary hesitation. The alpha-adrenergic blockade causes orthostatic hypotension (feeling lightheaded when standing up).

The OCD evidence. The original Clomipramine Collaborative Study Group trials in 1991 enrolled 520 adults across 21 centres and showed clomipramine substantially outperformed placebo on both Y-BOCS and NIMH global OCD scales. That was the basis for FDA approval. Since then, head-to-head comparisons have been more nuanced. A 2024 systematic review and meta-analysis found clomipramine remained more effective than SSRIs even after correcting for risk of bias, with a Hedges' G effect size of -0.59 versus placebo (about a 4.2-point Y-BOCS reduction). Pediatric trials show a similar pattern: clomipramine produces a greater treatment effect than SSRIs in children with OCD, though the side-effect burden is the reason it's still typically tried second. For treatment-resistant cases, intravenous clomipramine has been shown to work in patients who didn't respond to oral dosing, likely because it bypasses first-pass metabolism and gets more parent compound into circulation.

Premature ejaculation. This is the off-label use with the strongest evidence. A randomised double-blind study with stopwatch assessment found that 25 mg of on-demand clomipramine produced a 4-fold increase in intravaginal ejaculation latency time, far more than 20 mg paroxetine, which produced only a 1.4-fold increase. The best window was 3 to 4 hours after dosing. A 2021 meta-analysis confirmed that under 50 mg, higher doses produce longer latencies without raising the rate of side effects. For men who don't respond to 25 mg as needed, low daily dosing of 10-30 mg has been shown to extend latency from 25 seconds to over 3 minutes.

How it works for women. Most antidepressant research has historically been done on men, but the data we have on clomipramine in women is interesting and not what you might expect. An Italian study of 50 OCD patients found that women had a better antiobsessional response than men, with the difference being more pronounced in the clomipramine-treated group. The authors suggested reproductive hormones may play a role in serotonergic responsivity. The pharmacokinetics differ too. Women tend to have higher plasma concentrations of clomipramine than men at the same dose, partly because of slower hydroxylation clearance. This means women may need slightly lower doses to hit the same therapeutic level, and may also experience side effects sooner. A comparative study of sertraline vs clomipramine in OCD found symptom presentations also differ: women tend to present later in life and with more aggressive obsessions, while men have more sexual and symmetry obsessions. The practical takeaway: clomipramine appears to work at least as well, possibly better, in women, but starting low is more important.

Older adults. Sensitivity to anticholinergic and cardiovascular side effects increases with age. UK guidance suggests starting at 10 mg daily in older adults rather than 25 mg, and titrating more slowly. There's also a long-term concern: chronic anticholinergic burden has been linked to elevated dementia risk in epidemiological studies. For older patients, this is part of the calculus.

Limitations of the evidence. Most OCD trials are short (8-12 weeks), and the field has known publication bias issues. The 2024 meta-analysis explicitly noted that high-bias trials show inflated effect sizes, and the corrected effect for clomipramine was smaller than originally reported. Most placebo-controlled trials were done before 2007, so there isn't great modern data. Long-term efficacy beyond a year is documented but not robustly studied. For PE, study sizes are generally small (most under 100 men), and the IELT measurement can be variable. The effect is real, but individual response varies a lot.

Why it's a second-line agent. The honest answer: SSRIs are easier to live with. A recent expert review noted that when adjusted for publication year and population characteristics, clomipramine and SSRIs have similar effect sizes, so the marginal efficacy advantage doesn't always justify the side-effect burden. Where clomipramine wins is severity. For people whose OCD has not yielded to one or two SSRI trials at adequate doses for 8-12 weeks, the case for switching to clomipramine is strong.

Dosage:

For OCD: Start at 25 mg daily (10 mg if older or sensitive), preferably at bedtime to manage sedation. Titrate up by 25 mg every 4-7 days as tolerated. Most people land between 100-250 mg per day. The first 2 weeks should not exceed 100 mg

For premature ejaculation (on-demand): 25 mg taken 3-6 hours before sex. Some respond to 15 mg. Going above 50 mg doesn't add benefit and just increases side effects

For premature ejaculation (daily, if on-demand fails): 10-30 mg daily

Splitting doses: During titration, split with meals to reduce nausea. Once stable, the full dose can be taken at bedtime

Women: Consider starting at 10-25 mg and titrating more slowly. Plasma levels run higher at the same dose, so the same target may be reachable on less drug

Older adults: Start at 10 mg, titrate slowly, and watch for dizziness on standing and confusion

Hard ceiling: 250 mg per day in adults. Above this, seizure risk climbs sharply (about 0.5% at 250 mg, over 2% at 300+ mg)

Stopping: Never stop abruptly. Taper by about 25% every 2-4 weeks. The cholinergic rebound can be severe (nausea, insomnia, sweating, anxiety)

Time to effect: OCD response usually takes 6-12 weeks at full dose. PE effect is immediate when used on-demand

Here's what you can expect:

For OCD, expect a slow climb. The first few weeks are mostly about managing side effects while you titrate. Real symptom relief usually starts around week 4-6 and continues to deepen out to week 12. People typically describe it as the obsessive thoughts losing their grip, becoming easier to ignore rather than disappearing entirely. A 30-40% reduction in Y-BOCS score is considered a good response.

For premature ejaculation, the effect is almost mechanical. Most men taking 25 mg three to four hours before sex see latency extend from under a minute to several minutes, sometimes much longer. Some report a slight numbing or reduced sensation, which is typically the trade-off.

The first two weeks of any dose change tend to be the worst for side effects. Most settle as your body adapts.

Side effects & risks:

Common and dose-dependent: dry mouth, constipation, sedation, weight gain (5-10 lbs is typical over months), blurred vision, sexual dysfunction (delayed orgasm or anorgasmia in women, delayed/painful ejaculation in men), sweating, dizziness on standing, and tremor

Seizures are real and dose-dependent. About 0.5% at doses up to 250 mg, climbing above 2% past 300 mg. Don't push past 250 mg without a strong reason and close monitoring

Cardiac: QT prolongation and arrhythmia risk, especially in people with existing cardiac issues or on other QT-prolonging drugs. Baseline and on-treatment ECG matter

Serotonin syndrome: mainly when combined with other serotonergic agents (SSRIs, SNRIs, MAOIs, tramadol, triptans, MDMA, St John's Wort). Clomipramine is one of the strongest serotonergic drugs available, the risk is real if you stack

Hyponatremia (low sodium), more common in older adults

Liver enzyme elevations, usually mild

Black box warning: like all antidepressants, increased risk of suicidal ideation in those under 25 during the first few weeks

CYP2D6 interactions: fluoxetine and paroxetine inhibit the enzyme that breaks clomipramine down, leading to dramatically higher levels. The combination should be done with blood-level monitoring if at all. Genetic CYP2D6 variants can produce up to a 40-fold difference in plasma levels at the same dose

Hard contraindications: any MAOI within the last 14 days (5+ weeks for fluoxetine), known cardiac conduction abnormalities, recent heart attack, narrow-angle glaucoma, and pregnancy if avoidable. Clomipramine has been associated with congenital heart defects and neonatal withdrawal

Withdrawal: stopping abruptly causes a cholinergic rebound (nausea, insomnia, sweating, dizziness, anxiety) that can be severe. Always taper

🩸

Blood markers

ECG (baseline QTc), fasting glucose and lipid panel, liver enzymes (ALT, AST), sodium, and TSH before starting. A basic metabolic panel with magnesium is useful if you have any electrolyte concerns.

Recheck ECG after reaching your target dose, then yearly. Liver enzymes and sodium at 4-6 weeks, then every 6-12 months. Weight, glucose, and lipids every 6 months given the metabolic side effect profile.

Plasma clomipramine levels are worth checking if you're on doses above 200 mg or combining with another serotonergic drug. The 40-fold variation between fast and slow CYP2D6 metabolisers can make the difference between therapeutic and toxic.

Who actually needs the full workup: anyone going above 150 mg, anyone over 50, anyone with cardiac history, anyone on multiple serotonergic or QT-prolonging drugs. For someone using 25 mg on-demand for PE a few times a month, an ECG and a baseline metabolic panel are reasonable; routine rechecks are likely overkill.

Prescription-only in most countries.